Share on StockTwits

Hikma Pharmaceuticals Plc (LON:HIK)‘s stock had its “overweight” rating restated by stock analysts at JPMorgan Chase & Co. in a report issued on Tuesday. They currently have a GBX 1,400 ($23.77) price objective on the stock. JPMorgan Chase & Co.’s target price points to a potential downside of 14.58% from the company’s current price.

Hikma Pharmaceuticals Plc (LON:HIK) traded down 0.43% on Tuesday, hitting GBX 1639.00. The stock had a trading volume of 205,007 shares. Hikma Pharmaceuticals Plc has a one year low of GBX 903.50 and a one year high of GBX 1733.00. The stock’s 50-day moving average is GBX 1634. and its 200-day moving average is GBX 1438.68. The company’s market cap is £3.241 billion.

A number of other analysts have also recently weighed in on HIK. Analysts at Barclays reiterated an “overweight” rating on shares of Hikma Pharmaceuticals Plc in a research note on Monday, June 9th. They now have a GBX 1,890 ($32.08) price target on the stock. Finally, analysts at Jefferies Group raised their price target on shares of Hikma Pharmaceuticals Plc from GBX 1,500 ($25.46) to GBX 1,600 ($27.16) in a research note on Thursday, May 15th. They now have a “hold” rating on the stock. Six research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of GBX 1,590 ($26.99).

Hikma Pharmaceuticals PLC is engaged in the development, manufacture and marketing of a range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.